ABIONYX Pharma SA (ABNX.PA)
EUR 1.25
(2.46%)
EUR 1.25
(2.46%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.1 Million EUR | -64.97% |
| 2022 | 3.14 Million EUR | -19.49% |
| 2021 | 3.9 Million EUR | 0.0% |
| 2020 | - EUR | -100.0% |
| 2019 | 23 Thousand EUR | -95.4% |
| 2018 | 500 Thousand EUR | -91.41% |
| 2017 | 5.82 Million EUR | -13.8% |
| 2016 | 6.75 Million EUR | 10.85% |
| 2015 | 6.09 Million EUR | 22.08% |
| 2014 | 4.99 Million EUR | 23.32% |
| 2013 | 4.04 Million EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 857 Thousand EUR | 0.0% |
| 2023 Q1 | 2.93 Million EUR | -6.78% |
| 2023 Q3 | 2.57 Million EUR | -12.12% |
| 2023 Q4 | 1.1 Million EUR | -57.24% |
| 2023 FY | 1.1 Million EUR | -64.97% |
| 2023 Q2 | 2.93 Million EUR | 0.0% |
| 2022 Q2 | 3.34 Million EUR | 0.0% |
| 2022 Q3 | 3.14 Million EUR | -5.9% |
| 2022 FY | 3.14 Million EUR | -19.49% |
| 2022 Q1 | 3.34 Million EUR | -14.45% |
| 2022 Q4 | 3.14 Million EUR | 0.0% |
| 2021 Q4 | 3.9 Million EUR | 0.0% |
| 2021 FY | 3.9 Million EUR | 0.0% |
| 2021 Q3 | 3.9 Million EUR | 3449.09% |
| 2021 Q2 | 110 Thousand EUR | 0.0% |
| 2021 Q1 | 110 Thousand EUR | 0.0% |
| 2020 Q1 | - EUR | -100.0% |
| 2020 Q3 | - EUR | 0.0% |
| 2020 Q4 | - EUR | 0.0% |
| 2020 Q2 | - EUR | 0.0% |
| 2020 FY | - EUR | -100.0% |
| 2019 Q4 | 23 Thousand EUR | 0.0% |
| 2019 Q3 | 23 Thousand EUR | -96.99% |
| 2019 Q2 | 765 Thousand EUR | 0.0% |
| 2019 Q1 | 765 Thousand EUR | 53.0% |
| 2019 FY | 23 Thousand EUR | -95.4% |
| 2018 FY | 500 Thousand EUR | -91.41% |
| 2018 Q4 | 500 Thousand EUR | 0.0% |
| 2018 Q3 | 500 Thousand EUR | -92.3% |
| 2018 Q2 | 6.49 Million EUR | 0.0% |
| 2018 Q1 | 6.49 Million EUR | 11.51% |
| 2017 Q3 | 5.82 Million EUR | 6.55% |
| 2017 Q2 | 5.46 Million EUR | 0.0% |
| 2017 Q1 | 5.46 Million EUR | -19.1% |
| 2017 FY | 5.82 Million EUR | -13.8% |
| 2017 Q4 | 5.82 Million EUR | 0.0% |
| 2016 Q2 | 6.08 Million EUR | 0.0% |
| 2016 FY | 6.75 Million EUR | 10.85% |
| 2016 Q1 | 6.08 Million EUR | -0.18% |
| 2016 Q3 | 6.75 Million EUR | 11.05% |
| 2016 Q4 | 6.75 Million EUR | 0.0% |
| 2015 Q3 | 6.09 Million EUR | 9.06% |
| 2015 Q1 | - EUR | -100.0% |
| 2015 Q4 | 6.09 Million EUR | 0.0% |
| 2015 FY | 6.09 Million EUR | 22.08% |
| 2015 Q2 | 5.58 Million EUR | 0.0% |
| 2014 FY | 4.99 Million EUR | 23.32% |
| 2014 Q3 | 4.99 Million EUR | 0.0% |
| 2014 Q4 | 4.99 Million EUR | 0.0% |
| 2014 Q1 | - EUR | 0.0% |
| 2013 FY | 4.04 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ABIVAX Société Anonyme | 44.69 Million EUR | 97.537% |
| Adocia SA | 4.54 Million EUR | 75.749% |
| Aelis Farma SA | 2.04 Million EUR | 46.24% |
| Biophytis S.A. | 3.11 Million EUR | 64.609% |
| Advicenne S.A. | 15.89 Million EUR | 93.074% |
| genOway Société anonyme | 5.51 Million EUR | 80.052% |
| IntegraGen SA | 642.28 Thousand EUR | -71.421% |
| Medesis Pharma S.A. | 1.2 Million EUR | 8.25% |
| Neovacs S.A. | 650 Thousand EUR | -69.385% |
| NFL Biosciences SA | 39.2 Thousand EUR | -2708.459% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 74.727% |
| Quantum Genomics Société Anonyme | 1.96 Million EUR | 43.836% |
| Sensorion SA | 1.24 Million EUR | 11.275% |
| Theranexus Société Anonyme | 2.46 Million EUR | 55.257% |
| TME Pharma N.V. | - EUR | -Infinity% |
| Valbiotis SA | 3.89 Million EUR | 71.755% |
| TheraVet SA | 1 Million EUR | -10.034% |
| Valerio Therapeutics Société anonyme | 6.9 Million EUR | 84.057% |
| argenx SE | 15.35 Million EUR | 92.829% |
| BioSenic S.A. | 15.57 Million EUR | 92.93% |
| Celyad Oncology SA | 902 Thousand EUR | -22.062% |
| DBV Technologies S.A. | 4.52 Million USD | 75.674% |
| Galapagos NV | 4.94 Million EUR | 77.731% |
| Genfit S.A. | 62.25 Million EUR | 98.231% |
| GeNeuro SA | 6.49 Million EUR | 83.041% |
| Hyloris Pharmaceuticals SA | 344 Thousand EUR | -220.058% |
| Innate Pharma S.A. | 30.6 Million EUR | 96.403% |
| Inventiva S.A. | 25.61 Million EUR | 95.702% |
| MaaT Pharma SA | 5.42 Million EUR | 79.705% |
| MedinCell S.A. | 52.8 Million EUR | 97.915% |
| Nanobiotix S.A. | 41.66 Million EUR | 97.357% |
| Onward Medical N.V. | 16.3 Million EUR | 93.248% |
| Oryzon Genomics S.A. | 3.45 Million EUR | 68.093% |
| OSE Immunotherapeutics SA | 35.5 Million EUR | 96.899% |
| Oxurion NV | 117 Thousand EUR | -841.026% |
| Pharming Group N.V. | 123.65 Million EUR | 99.11% |
| Poxel S.A. | 40.14 Million EUR | 97.257% |
| GenSight Biologics S.A. | 1.04 Million EUR | -5.057% |
| Transgene SA | 17 Thousand EUR | -6376.471% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 2.87 Billion EUR | 99.962% |
| Valneva SE | 132.76 Million EUR | 99.171% |
| Vivoryon Therapeutics N.V. | - EUR | -Infinity% |